Market Cap 2.80B
Revenue (ttm) 47.07M
Net Income (ttm) -223.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475.59%
Debt to Equity Ratio 0.00
Volume 393,400
Avg Vol 921,456
Day's Range N/A - N/A
Shares Out 65.12M
Stochastic %K 7%
Beta 2.18
Analysts Strong Sell
Price Target $60.50

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 5300
Address:
500 North Beacon Street, 4th Floor, Watertown, United States
Tumble51
Tumble51 Jul. 25 at 1:40 PM
$CADL Wall Street thinks more of $KYMR with NO PHASE 1 completed than they do of TAK , hahahaha $45 …no phase 1, done ..no ph2 or ph3 Read the truth and weep
1 · Reply
ZacksResearch
ZacksResearch Jul. 18 at 6:03 PM
$KYMR surges 70.7% — what's fueling the rally? 🚀 Kymera's collaboration with $GILD on a novel CDK2-targeting drug has impressed investors, potentially offering more precise cancer treatments. The deal brings an $85M upfront payment and up to $750M in future payments. 💰 Despite a setback in its Sanofi deal, KYMR has outperformed the industry, sector, and S&P 500. See why KYMR could be a hidden gem in biotech 👉 https://www.zacks.com/stock/news/2591761/kymera-surges-70-in-3-months-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2591761-body-2543&ADID=SYND_STOCKTWITS_TWEET_2_2591761_BODY_2543
0 · Reply
dka79
dka79 Jul. 18 at 5:22 PM
$KYMR blackrock is 5% share holder now check filing
0 · Reply
ZacksResearch
ZacksResearch Jul. 18 at 1:08 PM
$KYMR up 70% in 3 months — still room to run or time to lock in gains? The $750M GILD oncology deal plus pipeline traction in targeted protein degradation (TPD) have powered the surge. Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2591761/kymera-surges-70-in-3-months-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2591761-teaser-2516&ADID=SYND_STOCKTWITS_TWEET_2_2591761_TEASER_2516
1 · Reply
TipRanks
TipRanks Jul. 8 at 10:07 AM
Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow https://www.tipranks.com/news/article/morgan-stanley-puts-these-2-stocks-on-its-buy-list-heres-why-you-should-follow $PRMB $KYMR
0 · Reply
JarvisFlow
JarvisFlow Jul. 7 at 1:00 PM
B. Riley Securities updates rating for Kymera Therapeutics ( $KYMR ) to Neutral, target set at 36 → 41.
0 · Reply
JarvisFlow
JarvisFlow Jul. 7 at 1:00 PM
B. Riley Securities has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Neutral with a target price of 41 → 38.
0 · Reply
JarvisFlow
JarvisFlow Jul. 7 at 10:30 AM
JP Morgan has updated their rating for Kymera Therapeutics ( $KYMR ) to Overweight with a price target of 57.
0 · Reply
Grouphome
Grouphome Jul. 3 at 1:58 PM
$KYMR yep
1 · Reply
DonCorleone77
DonCorleone77 Jun. 29 at 9:50 PM
$KYMR $SNY Kymera Therapeutics price target raised to $54 from $51 at BofA BofA raised the firm's price target on Kymera Therapeutics (KYMR) to $54 from $51 and keeps a Buy rating on the shares. The company announced that its partner Sanofi (SNY) decided to advance KT-485, an oral IRAK4 degrader, into the clinic and discontinue development of KT-474, the analyst tells investors in a research note. The firm says that while the KT-474 update will set back the program by several years, the update reinforces Kymera and Sanofi's commitment to developing the best possible IRAK4 degrader. It remains "encouraged" by Kymera's "strong" business development capabilities to establish collaborations with large pharma for several assets in its pipeline.
0 · Reply
Latest News on KYMR
Kymera Therapeutics Announces Proposed Public Offering

Jun 25, 2025, 4:05 PM EDT - 5 weeks ago

Kymera Therapeutics Announces Proposed Public Offering


Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Jun 25, 2025, 7:05 AM EDT - 5 weeks ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update


Kymera: Protein Degradation Could Drive Dupixent-Like Value

Dec 7, 2024, 1:07 AM EST - 8 months ago

Kymera: Protein Degradation Could Drive Dupixent-Like Value


Tumble51
Tumble51 Jul. 25 at 1:40 PM
$CADL Wall Street thinks more of $KYMR with NO PHASE 1 completed than they do of TAK , hahahaha $45 …no phase 1, done ..no ph2 or ph3 Read the truth and weep
1 · Reply
ZacksResearch
ZacksResearch Jul. 18 at 6:03 PM
$KYMR surges 70.7% — what's fueling the rally? 🚀 Kymera's collaboration with $GILD on a novel CDK2-targeting drug has impressed investors, potentially offering more precise cancer treatments. The deal brings an $85M upfront payment and up to $750M in future payments. 💰 Despite a setback in its Sanofi deal, KYMR has outperformed the industry, sector, and S&P 500. See why KYMR could be a hidden gem in biotech 👉 https://www.zacks.com/stock/news/2591761/kymera-surges-70-in-3-months-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2591761-body-2543&ADID=SYND_STOCKTWITS_TWEET_2_2591761_BODY_2543
0 · Reply
dka79
dka79 Jul. 18 at 5:22 PM
$KYMR blackrock is 5% share holder now check filing
0 · Reply
ZacksResearch
ZacksResearch Jul. 18 at 1:08 PM
$KYMR up 70% in 3 months — still room to run or time to lock in gains? The $750M GILD oncology deal plus pipeline traction in targeted protein degradation (TPD) have powered the surge. Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2591761/kymera-surges-70-in-3-months-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2591761-teaser-2516&ADID=SYND_STOCKTWITS_TWEET_2_2591761_TEASER_2516
1 · Reply
TipRanks
TipRanks Jul. 8 at 10:07 AM
Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow https://www.tipranks.com/news/article/morgan-stanley-puts-these-2-stocks-on-its-buy-list-heres-why-you-should-follow $PRMB $KYMR
0 · Reply
JarvisFlow
JarvisFlow Jul. 7 at 1:00 PM
B. Riley Securities updates rating for Kymera Therapeutics ( $KYMR ) to Neutral, target set at 36 → 41.
0 · Reply
JarvisFlow
JarvisFlow Jul. 7 at 1:00 PM
B. Riley Securities has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Neutral with a target price of 41 → 38.
0 · Reply
JarvisFlow
JarvisFlow Jul. 7 at 10:30 AM
JP Morgan has updated their rating for Kymera Therapeutics ( $KYMR ) to Overweight with a price target of 57.
0 · Reply
Grouphome
Grouphome Jul. 3 at 1:58 PM
$KYMR yep
1 · Reply
DonCorleone77
DonCorleone77 Jun. 29 at 9:50 PM
$KYMR $SNY Kymera Therapeutics price target raised to $54 from $51 at BofA BofA raised the firm's price target on Kymera Therapeutics (KYMR) to $54 from $51 and keeps a Buy rating on the shares. The company announced that its partner Sanofi (SNY) decided to advance KT-485, an oral IRAK4 degrader, into the clinic and discontinue development of KT-474, the analyst tells investors in a research note. The firm says that while the KT-474 update will set back the program by several years, the update reinforces Kymera and Sanofi's commitment to developing the best possible IRAK4 degrader. It remains "encouraged" by Kymera's "strong" business development capabilities to establish collaborations with large pharma for several assets in its pipeline.
0 · Reply
TaxiBiotech_
TaxiBiotech_ Jun. 29 at 4:58 PM
$KYMR KYMERA Updates its pipeline for IRAK4 degrader: Phase 2 KT-474 is discontinued. They’re now trying a new degrader: KT-485. Old pipeline vs updated:
0 · Reply
TaxiBiotech_
TaxiBiotech_ Jun. 29 at 4:53 PM
$KYMR Kymera Therapeutics $KYMR announces a $250.8M public offering (5M shares + 655K pre-funded warrants), with an option to purchase an additional 855K shares. 💵 Offering price: $44.00 📅 Expected closing date: June 30, 2025 📌 Shares outstanding: 65M (Est. fully diluted~80M) 🎯 Use of proceeds: to fund its pipeline of oral protein degraders for immunological diseases.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 27 at 10:20 AM
$KYMR Kymera Therapeutics 5.043M share Spot Secondary priced at $44.00 Morgan Stanley, JPMorgan, Jefferies, TD Securities and Leerink acted as joint book running managers for the offering.
0 · Reply
ZacksResearch
ZacksResearch Jun. 26 at 7:15 PM
$KYMR drops on Sanofi exit — but here's the bullish twist 📉➡️📈 Sanofi pulled the plug on KT-474, hitting shares, but the new Gilead oncology collaboration signals fresh upside potential. Full breakdown of the double-edged update here 👉 https://www.zacks.com/stock/news/2554322/kymr-collaborates-with-gild-stock-down-on-sanofi-deal-update?cid=sm-stocktwits-2-2554322-body-262&ADID=SYND_STOCKTWITS_TWEET_2_2554322_BODY_262
0 · Reply
ZacksResearch
ZacksResearch Jun. 26 at 12:47 PM
$KYMR slips as Sanofi drops KT-474 development. ⚠️ Despite a promising deal with $GILD and a 15.5% YTD gain, the stock sees red due to Sanofi's decision not to advance KT-474, impacting potential milestone payments. 📉 Discover the full story here 👉 https://www.zacks.com/commentary/2554322/kymr-collaborates-with-gild-stock-down-on-sanofi-deal-update?cid=sm-stocktwits-2-2554322-body-156&ADID=SYND_STOCKTWITS_TWEET_2_2554322_BODY_156
0 · Reply
JarvisFlow
JarvisFlow Jun. 26 at 12:30 PM
HC Wainwright & Co. has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Buy with a target price of 54 → 60.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 25 at 9:40 PM
$KYMR Kymera Therapeutics announces $250M common stock offering Kymera Therapeutics announced that it has commenced an underwritten public offering of $250M of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. Kymera intends to use the net proceeds from the offering to continue to advance its pipeline of preclinical and clinical degrader programs that are designed to address large patient populations with significant need and clear commercial opportunity, and for working capital and other general corporate purposes. Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen and Leerink Partners are acting as joint book-running managers for the offering.
0 · Reply
redistributeW
redistributeW Jun. 25 at 8:25 PM
$KYMR And there it is Propose stock offering
1 · Reply
StocktwitsNews
StocktwitsNews Jun. 25 at 2:28 PM
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit $GILD $KYMR $VTI https://stocktwits.com/news/equity/markets/gilead-sciences-signs-750-million-dollar-deal-for-cancer-drug-with-kymera-therapeutics/chmJlNmRRES
0 · Reply
DonCorleone77
DonCorleone77 Jun. 25 at 11:19 AM
$GILD $KYMR Gilead sees Kymera deal lowering 2025 EPS by 2c-3c Gilead (GILD) and Kymera Therapeutics (KYMR) announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader program targeting cyclin-dependent kinase 2 with broad oncology treatment potential including in breast cancer and other solid tumors. Gilead does not exclude acquired IPR&D expenses from its non-GAAP financial measures, the company noted. This transaction with Kymera is expected to reduce Gilead's GAAP and non-GAAP 2025 EPS by approximately 2c-3c, the company stated.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 25 at 11:15 AM
$KYMR $GILD Gilead, Kymera enter license agreement for molecular glue degrader program Gilead (GILD) and Kymera Therapeutics (KYMR) announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader program targeting cyclin-dependent kinase 2 with broad oncology treatment potential including in breast cancer and other solid tumors. Under the terms of the agreement, Kymera is eligible to receive up to $750M in total payments, including up to $85M in upfront and potential option exercise payments. In addition, Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option to exclusively license the program, Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 25 at 11:10 AM
$KYMR $SNY Kymera says Sanofi to advance KT-485 into clinical testing Kymera Therapeutics (KYMR) announced an update to its IRAK4 partnership with Sanofi (SNY). Sanofi has informed Kymera that KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera has discovered and characterized through preclinical studies, has been selected to advance into clinical studies. Following extensive preclinical work supporting its robust development potential, KT-485 is being prioritized for development under the companies' existing IRAK4 collaboration, and is expected to advance into Phase 1 testing next year. Based on the planned development of KT-485, Sanofi will not advance KT-474. In conjunction with its plans to advance KT-485, Sanofi also communicated its decision to exercise its participation election right for the IRAK4 target under the terms of the companies' collaboration agreement. Under the agreement, Kymera achieved a $20M milestone in the second quarter of 2025 related to preclinical activities associated with KT-485. Kymera is eligible to receive up to $975M of potential clinical, regulatory and commercial milestones related to KT-485, including an additional milestone upon the start of Phase 1 clinical testing.
0 · Reply